• Molecular NameZileuton
  • Synonymzileuton; Zileutonum [INN-Latin]
  • Weight236.295
  • Drugbank_IDDB00744
  • ACS_NO111406-87-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.11
  • pkaN/A
  • LogD (pH=7, predicted)2.11
  • Solubility (experiment)0.101 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.22
  • LogSw (predicted, AB/LogsW2.0)0.46
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA94.8
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation.
  • Absorption_value100.0
  • Absorption (description)Rapidly and almost completely absorbed. The absolute bioavailability is unknown.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding93.4
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmZileuton and its N-dehydroxylated metabolite are oxidatively metabolized by the cytochrome P450 isoenzymes 1A2, 2C9 and 3A4.
  • Half life2.5 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A